Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 3/2023

20-06-2023 | Acute Myeloid Leukemia | review

ASH 2022—new developments in acute myeloid leukemia

Author: Prof. Dr. Michael Pfeilstöcker

Published in: memo - Magazine of European Medical Oncology | Issue 3/2023

Login to get access

Summary

Recent years have provided progress for the treatment of acute myeloid leukemia (AML) patients by translating insights from basic research on AML biology into new drugs and concepts. The latest developments presented at the 2022 annual meeting of the American Society of Hematology (ASH) are covered in this review, including discussion of new classifications, treatment of elderly unfit patients, and new approaches towards allogeneic transplantation.
Literature
1.
Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36(7):1703–19.CrossRefPubMedPubMedCentral
2.
Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200–28.CrossRefPubMed
3.
Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–77.CrossRefPubMed
4.
Huber S, Baer C, Hutter S, et al. AML and MDS classification according to who 2022 and international consensus classification: do we invent a babylonian confusion of languages? Blood. 2022;140(Supplement 1):555–6.CrossRef
5.
Song GY, Kim T, Ahn SY, et al. Prognostic predictability of 2022 European Leukemianet (ELN) risk stratification in the real world. Blood. 2022;140(Supplement 1):1018–9.CrossRef
6.
Döhner H, Pratz KW, DiNardo CD, et al. ELN risk stratification is not predictive of outcomes for treatment-naïve patients with acute myeloid leukemia treated with Venetoclax and Azacitidine. Blood. 2022;140(Supplement 1):1441–4.CrossRef
7.
Hernández Sánchez A, Ramiro AV, Strang E, et al. Machine learning allows the identification of new co-mutational patterns with prognostic implications in NPM1 mutated AML—results of the European Harmony Alliance. Blood. 2022;140(Supplement 1):739–42.CrossRef
8.
Pratz KW, Jonas BA, Pullarkat VA, et al. Long-term follow-up of the phase 3 Viale—a clinical trial of Venetoclax plus Azacitidine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Blood. 2022;140(Supplement 1):529–31.CrossRef
9.
Willekens C, Chraibi S, Decroocq J, et al. Reduced Venetoclax exposition to seven days of Azacitidine is efficient in treatment-naïve patients with acute myeloid leukemia. Blood. 2022;140(Supplement 1):537–8.CrossRef
10.
Reville PK, Kantarjian H, Borthakur G, et al. Venetoclax added to Cladribine (CLAD) + low dose AraC (LDAC) alternating with Azacitidine (AZA) is highly active as frontline therapy in older patients with newly diagnosed acute Myeloid leukemia in a phase 2 study. Blood. 2022;140(Supplement 1):9041–3.CrossRef
11.
Chua CC, Loo S, Reynolds J, et al. High response and prolonged treatment-free remission after a short-course of modified intensive chemotherapy and Venetoclax in elderly AML: an updated analysis of the caveat trial. Blood. 2022;140(Supplement 1):1708–10.CrossRef
12.
Desikan SP, Konopleva M, Takahashi K, et al. Updated phase IIb results of Venetoclax with FLAG-IDA in relapsed or refractory acute myeloid leukemia. Blood. 2022;140(Supplement 1):534–6.CrossRef
13.
Daver N, Senapati J, Maiti A, et al. Phase I/II study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in patients (pts) with newly diagnosed (ND) older/unfit or high-risk acute Myeloid leukemia (AML) and relapsed/refractory (R/R) AML. Blood. 2022;140(Supplement 1):141–4.CrossRef
14.
Daver N, Montesinos P, Aribi A, et al. Abstr 62 broad activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax triplet in high-risk patients with relapsed/refractory acute Myeloid leukemia (AML). Blood. 2022;140(Supplement 1):145–9.CrossRef
15.
Short N, DiNardo CD, Daver N, et al. Updated results from a phase I/II study of the triplet combination of Azacitidine, Venetoclax and Gilteritinib for patients with FLT3-mutated acute Myeloid leukemia. Blood. 2022;140(Supplement 1):2007–9.CrossRef
16.
Wang ES, Montesinos P, Minden MD, et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood. 2022;140(17):1845–57.CrossRefPubMed
17.
Daver N, Perl AE, Maly J, et al. Venetoclax plus Gilteritinib for FLT3-mutated relapsed/refractory acute Myeloid leukemia. J Clin Oncol. 2022;40(35):4048–59.CrossRefPubMedPubMedCentral
18.
Janssen M, Schmidt C, Bruch PM, et al. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL‑1. Blood. 2022;140(24):2594–610.CrossRefPubMed
19.
Stelljes M, Middeke JM, Bug G, et al. In patients with relapsed/refractory AML sequential conditioning and immediate allogeneic stem cell transplantation (allo-HCT) results in similar overall and leukemia-free survival compared to intensive remission induction chemotherapy followed by Allo-HCT: results from the randomized phase III ASAP trial. Blood. 2022;140(Supplement 1):9–11.CrossRef
Metadata
Title
ASH 2022—new developments in acute myeloid leukemia
Author
Prof. Dr. Michael Pfeilstöcker
Publication date
20-06-2023
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 3/2023
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-023-00896-z

Other articles of this Issue 3/2023

memo - Magazine of European Medical Oncology 3/2023 Go to the issue

short review

Next generation drugs in urothelial cancer: adenoviruses in the treatment of BCG-unresponsive nonmuscle invasive bladder cancer

short review

ASH highlights 2022—multiple myeloma

case report

Hepatosplenic T-cell lymphoma with hemophagocytic lymphohistiocytosis, revealed by fever of unknown origin

short review

Lipid nanoparticles in the treatment of lung cancer—hype or hope?

short review

New developments in radiation oncology for head and neck cancers

short review

Current systemic treatment options and new developments in palliative first-line treatment of head and neck squamous cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits